Theragnostics Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
8
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$2.5M
Theragnostics General Information
Description
Developer of molecular radiotherapy and molecular imaging diagnostic products designed for the treatment of cancer patients. The company's radioactive labeled drugs help to improve patient outcomes by providing physicians access to the superior sensitivity and specificity of PET imaging, enabling clinicians to handle both the management and treatment of cancer patients, from initial diagnosis through response to therapy.
Contact Information
Website
www.theragnostics.comCorporate Office
- 21 Gloucester Place
- London W1U 8HR
- England, United Kingdom
Corporate Office
- 21 Gloucester Place
- London W1U 8HR
- England, United Kingdom
Theragnostics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 01-Jun-2023 | $2.5M | Completed | Generating Revenue | ||
| 4. Later Stage VC | 21-May-2021 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 28-Dec-2019 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC | 31-Aug-2017 | $3.69M | $3.69M | Completed | Clinical Trials - Phase 1 | |
| 1. Grant | 01-Jun-2016 | $910K | Completed | Startup |
Theragnostics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary |
Theragnostics Patents
Theragnostics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-201504064-D0 | Method and kits for preparing radionuclide complexes | Inactive | 10-Mar-2015 | ||
| AU-2016230890-A1 | Methods and kits for preparing radionuclide complexes | Active | 10-Mar-2015 | ||
| AU-2016230890-B2 | Methods and kits for preparing radionuclide complexes | Active | 10-Mar-2015 | ||
| CA-2979127-A1 | Methods and kits for preparing radionuclide complexes | Active | 10-Mar-2015 | ||
| CA-2979127-C | Methods and kits for preparing radionuclide complexes | Active | 10-Mar-2015 | C07F5/003 |
Theragnostics Signals
Theragnostics Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Innovate UK | Government |
Theragnostics FAQs
-
When was Theragnostics founded?
Theragnostics was founded in 2013.
-
Where is Theragnostics headquartered?
Theragnostics is headquartered in London, United Kingdom.
-
What is the size of Theragnostics?
Theragnostics has 8 total employees.
-
What industry is Theragnostics in?
Theragnostics’s primary industry is Diagnostic Equipment.
-
Is Theragnostics a private or public company?
Theragnostics is a Private company.
-
What is the current valuation of Theragnostics?
The current valuation of Theragnostics is .
-
What is Theragnostics’s current revenue?
The current revenue for Theragnostics is .
-
How much funding has Theragnostics raised over time?
Theragnostics has raised $11.4M.
-
Who are Theragnostics’s investors?
Innovate UK has invested in Theragnostics.
-
When was Theragnostics acquired?
Theragnostics was acquired on 01-Jun-2023.
-
Who acquired Theragnostics?
Theragnostics was acquired by Ariceum.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process